KR20230165799A - L-아스파라기나제의 제제 - Google Patents

L-아스파라기나제의 제제 Download PDF

Info

Publication number
KR20230165799A
KR20230165799A KR1020237037007A KR20237037007A KR20230165799A KR 20230165799 A KR20230165799 A KR 20230165799A KR 1020237037007 A KR1020237037007 A KR 1020237037007A KR 20237037007 A KR20237037007 A KR 20237037007A KR 20230165799 A KR20230165799 A KR 20230165799A
Authority
KR
South Korea
Prior art keywords
formulation
asparaginase
administered
present disclosure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237037007A
Other languages
English (en)
Korean (ko)
Inventor
세카르 카나푸람
하리파다 마이티
구이펑 지앙
로자 나르왈
Original Assignee
재즈 파마슈티칼즈 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재즈 파마슈티칼즈 아일랜드 리미티드 filed Critical 재즈 파마슈티칼즈 아일랜드 리미티드
Publication of KR20230165799A publication Critical patent/KR20230165799A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020237037007A 2021-04-06 2022-04-05 L-아스파라기나제의 제제 Pending KR20230165799A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171429P 2021-04-06 2021-04-06
US63/171,429 2021-04-06
PCT/US2022/071562 WO2022217231A1 (en) 2021-04-06 2022-04-05 Formulations of l-asparaginase

Publications (1)

Publication Number Publication Date
KR20230165799A true KR20230165799A (ko) 2023-12-05

Family

ID=81748398

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037007A Pending KR20230165799A (ko) 2021-04-06 2022-04-05 L-아스파라기나제의 제제

Country Status (12)

Country Link
EP (1) EP4319818A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024515555A (cg-RX-API-DMAC10.html)
KR (1) KR20230165799A (cg-RX-API-DMAC10.html)
CN (1) CN117377494A (cg-RX-API-DMAC10.html)
AR (1) AR125301A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022256071A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023019862A2 (cg-RX-API-DMAC10.html)
CA (1) CA3213726A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023002983A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023014093A2 (cg-RX-API-DMAC10.html)
MX (1) MX2023011693A (cg-RX-API-DMAC10.html)
WO (1) WO2022217231A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022211829A1 (en) * 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103290A2 (en) 2006-03-03 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
DK3463308T4 (da) * 2016-06-01 2026-02-09 Servier Ip Uk Ltd Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf
JP2021505661A (ja) * 2017-11-30 2021-02-18 ジャズ ファーマシューティカルズ アイルランド リミテッド アスパラギナーゼを用いた治療法
CA3156066A1 (en) * 2019-10-25 2021-04-29 Mi Rim Choi Recombinant l-asparaginase

Also Published As

Publication number Publication date
AU2022256071A1 (en) 2023-10-19
MX2023011693A (es) 2023-12-15
JP2024515555A (ja) 2024-04-10
EP4319818A1 (en) 2024-02-14
WO2022217231A1 (en) 2022-10-13
CN117377494A (zh) 2024-01-09
BR112023019862A2 (pt) 2023-11-07
AR125301A1 (es) 2023-07-05
CO2023014093A2 (es) 2023-10-30
CA3213726A1 (en) 2022-10-13
CL2023002983A1 (es) 2024-04-12

Similar Documents

Publication Publication Date Title
USRE49736E1 (en) Pegylated L-asparaginase
JP5781931B2 (ja) 凍結乾燥した組換え型ｖｗｆ製剤
KR102758570B1 (ko) 재조합 산 알파-글루코시다제를 포함하는 제형
US20230173042A1 (en) Methods of treatment with asparaginase
US20080227691A1 (en) Blood Coagulation FVIII Analogues
JP6961061B2 (ja) 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ
JP2012506387A5 (cg-RX-API-DMAC10.html)
CN112661863A (zh) 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
US12564619B2 (en) Stable formulations of recombinant proteins
JP2023510268A (ja) Ｆｇｆ－２１コンジュゲート製剤
AU2022256071A1 (en) Formulations of l-asparaginase
CN103889445A (zh) 硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途
US20240197841A1 (en) Formulations of l-asparaginase
US12551540B2 (en) Dosing and administration of recombinant L-asparaginase
WO2024006981A1 (en) Anti-pd-1 antibody formulations
HK40073071A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
HK40047241A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
JP2023514541A (ja) 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療
JPWO2000049041A1 (ja) 蛋白質製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231026

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250317

Comment text: Request for Examination of Application